Vor Bio Employee Equity
Vor Bio Grants 71,200 Stock Awards to Seven New Employees Under Nasdaq Rule
Anonymous
Vor Bio (Nasdaq: VOR) granted stock awards to seven new employees on July 1, 2026, the company announced. The clinical-stage biotech gave out options to buy 71,200 shares of common stock, plus 15,150 restricted stock units, according to GlobeNewswire.
Both awards fall under Nasdaq Listing Rule 5635(c)(4), which lets companies give stock to new hires without a shareholder vote. It is a common tool biotech firms use to attract talent quickly.
Stock Options Come With a Ten-Year Window
The stock options give each new hire the right to buy shares at the closing price on July 1, 2026. That price is the exercise price — what they must pay per share later. The options stay open for ten years, giving employees a long runway to act, according to Financial Content.
Stock options only pay off if the share price rises above that exercise price. If Vor Bio's stock climbs over the next decade, new hires can buy shares cheaply and profit from the difference.
RSUs Vest Over Four Years With a One-Year Cliff
The 15,150 restricted stock units follow a four-year vesting schedule. A set portion of shares vest after the first 12 months — known as a "cliff." After that, the remaining shares vest monthly over the next 36 months, according to Stock Titan.
Vesting is tied to continued employment. If a new hire leaves before the cliff, they get nothing. This structure is designed to keep employees at the company for the long term.
Nasdaq Rule Allows Hiring Grants Without Shareholder Approval
Nasdaq Listing Rule 5635(c)(4) is an exemption built for new hires. It lets companies issue equity as an "inducement" — meaning a reason to join — without holding a shareholder vote. The rule requires public disclosure, which Vor Bio filed promptly, according to Market Screener.
Biotech companies use this rule often. Recruiting scientists and executives is competitive, and equity grants are a key part of compensation packages in the industry.
Vor Bio Continues to Build Out Its Clinical Team
Vor Bio is a clinical-stage company, meaning it has not yet brought a product to market. Adding seven new employees at once signals active growth in its operations or research programs, according to GlobeNewswire.
The company's Compensation Committee approved the grants, not the full Board. That is standard practice for routine equity awards. Vor Bio trades on Nasdaq under the ticker VOR.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
3
Reach
4
A
AnonymousAuthor
